Tyrosine Kinase Inhibitor Therapy: Resistance and Mutation Detection in Chronic Myeloid Leukemia Patients

The BCR-ABL1 fusion gene in the Philadelphia Chromosome, formed due to translocation between chromosome 9 and 22, leads to occurrence of Chronic Myeloid Leukemia. This is responsible for up to 15% of adult leukemia’s. Most patients treated with Tyrosine Kinase Inhibitor [TKI] imatinib mesylate achieve durable response but may undergo relapse at some stage. One of the mechanisms that may confer TKI resistance is Point mutation within BCR-ABL kinase and regulatory domain. We aim to focus on the TKIs, presence of mutations and identify the techniques used to detect the occurrence of the same in brief.

Author(s):

Ira Shukla* and Suneetha V

Abstract | Full-Text | PDF

Share this